0001209191-18-056044.txt : 20181024 0001209191-18-056044.hdr.sgml : 20181024 20181024161549 ACCESSION NUMBER: 0001209191-18-056044 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181022 FILED AS OF DATE: 20181024 DATE AS OF CHANGE: 20181024 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arnold Susan Elizabeth CENTRAL INDEX KEY: 0001755746 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38697 FILM NUMBER: 181136541 MAIL ADDRESS: STREET 1: C/O PHASEBIO PHARMACEUTICALS, INC. STREET 2: 1 GREAT VALLEY DRIVE, SUITE 30 CITY: MALVERN STATE: PA ZIP: 19355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PhaseBio Pharmaceuticals Inc CENTRAL INDEX KEY: 0001169245 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 030375697 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY STREET 2: SUITE 30 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: (610) 981-6500 MAIL ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY STREET 2: SUITE 30 CITY: MALVERN STATE: PA ZIP: 19355 FORMER COMPANY: FORMER CONFORMED NAME: Phase Biosciences Inc DATE OF NAME CHANGE: 20061013 FORMER COMPANY: FORMER CONFORMED NAME: DT BIOSCIENCES INC DATE OF NAME CHANGE: 20020315 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-10-22 0 0001169245 PhaseBio Pharmaceuticals Inc PHAS 0001755746 Arnold Susan Elizabeth C/O PHASEBIO PHARMACEUTICALS, INC. 1 GREAT VALLEY PARKWAY, SUITE 30 MALVERN PA 19355 0 1 0 0 VP, Preclinical and Chem. Common Stock 2018-10-22 4 C 0 2306 A 2306 D Warrants to Purchase Series B Preferred Stock 0.12 2018-10-22 4 M 0 103 0.00 D Series B Preferred Stock 103 0 D Series B Preferred Stock 2018-10-22 4 M 0 103 0.12 A Common Stock 103 2306 D Series B Preferred Stock 2018-10-22 4 C 0 2306 0.00 D Common Stock 2306 0 D Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. Represents the exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. /s/ Darren K. DeStefano, Attorney-in-Fact 2018-10-24